Seizures frequently result from an imbalance of excitation and inhibition due to a failure of inhibitory neurotransmission. Most agents that enhance GABA A receptor (GABA A R) function have antiseizure properties due to their ability to increase inhibitory neurotransmitter tone. The evidence linking epilepsy with dysfunction of GABAergic inhibition is substantial, and has been extensively reviewed [1] [2] [3] [4] .
GABA A Rs and epilepsy
GABA A Rs are pharmacologically complex, with binding sites for benzodiazepines (BZs), barbiturates, neurosteroids, general anesthetics, loreclezole, and the convulsant toxins, picrotoxin and bicuculline. Protein subunits from seven different subunit families 5 assemble to form pentameric 6 transmembrane chloride channels ( Fig. 1 ). In mammals, 16 11 , reducing the number of isoforms expressed in specific brain regions and individual neurons. The most common composition includes two a1, two b2 and a single g2 subunit; the d subunit is found instead of g in receptors expressed extrasynaptically. The subunits are arranged around a central water-filled pore, which gates to conduct Cl À ions when GABA is bound (Fig. 1 ). Individual subunit subtypes confer different sensitivities to GABA A R modulators including BZs 12 , loreclezole 13 and zinc ions 14 (Table 1) .
GABA A Rs are the target not only of the BZs, but other ASDs including barbiturates and agents like tiagabine and vigabatrin 1 that increase GABA concentration at the synapse. Bicuculline and picrotoxin, which are GABA A R antagonists, induce seizures in animals and epileptiform activity in brain slice preparations. Several animal models of epilepsy have altered GABA A R number or function 1, 2, 15 . GABA A R subunit expression is altered in the hippocampi of experimental animals with recurrent seizures 16 and in patients with temporal lobe epilepsy 17, 18 . Angelman's syndrome is a human neurodevelopmental disorder associated with severe mental retardation and epilepsy, which is linked to a deletion mutation on chromosome 15q11-13 20 in a region encoding the GABA A R b3 subunit 21 . Two mutations in the g2
subunit that impair GABA A R function 22 , K289 M 23 and R43Q 24 ,
have been linked to a human syndrome of childhood absence epilepsy and febrile seizures, and a loss-of-function mutation in the a1 subunit causes autosomal dominant Juvenile Myoclonic Epilepsy 25 . The R43Q mutation in the g2 subunit reduces BZ sensitivity 26 by altering GABA A R assembly [27] [28] [29] and trapping the receptor in the endoplasmic reticulum 30 . Other point mutations in 198 . Images modified from en.wikipedia.org/wiki/GABA_A_receptor, used with permission (public domain)]. Antiseizure Activity. BZs are effective against most experimental seizure types, but individual drugs vary in their potency/efficacy in specific seizure models and their other clinical effects. 45 BZs are particularly effective against convulsive seizures induced by pentylenetetrazol 46 and less effective against tonic seizures induced by maximal electroshock. 47 BZs also slow the development of kindling.
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GABA A R Subunits and BZ Pharmacology. BZ augmentation of GABA A R currents requires a g subunit, and the selectivity of BZ responsiveness is determined by which a subunits are present.
5,49
The BZ binding site is located in a cleft between the extracellular amino termini of the a and g subunits. 51 The a1 subunit results in a receptor with high affinity for the hypnotic, zolpidem, defining the ''BZ-1'' (or V-1) receptor type. 50 The a2 and a3 subunits result in receptors with moderate zolpidem affinity, termed BZ-2 receptors.
GABA A Rs containing the a5 subunit and/or the g3 subunit are sensitive to diazepam but not to zolpidem and are termed BZ-3 receptors. GABA A Rs with the a4 or a6 subunits are insensitive to most BZs. The subunit composition not only determines the affinity for particular BZs, but also the clinical/behavioral effect of the BZ at that receptor. The role of the a subunits in BZ pharmacology was revealed by the discovery of a single histidine (H) residue found in all BZ-sensitive a subunits (H101 in the rat a1 subunit), but not in the BZ-insensitive a4 or a6 subunits, which instead have a charged arginine (R) residue. This H residue was discovered in a strain of ''alcohol-non-tolerant'' rats, which were found to have a spontaneous point mutation in the a6 subunit (R100Q) that made their a6-containing GABA A Rs (found mostly in the cerebellum) diazepam-sensitive, accounting for their ethanol and BZ intolerance. 53 Mutation of R100 to H in a6 dramatically increased BZ binding in this normally insensitive subunit, while mutation of H101 to R in a1 reduced BZ sensitivity. 52 BZ-insensitive a subunit mutations were subsequently ''knocked-in'' to identify BZ actions at receptors containing that subunit. In homozygous a1(H101R) knock-in mice, the anxiolytic effect was intact, but
BZs were not protective against pentylenetetrazol-induced convulsions and did not produce sedation or amnesia, suggesting that binding to the (wild type) a1 subunit is responsible for sedative, amnestic and antiseizure actions. 54 Moreover, the sedative-hypnotic, zolpidem, showed no sedative effect in a1(H101R) mice. 55 Unfortunately, these findings underscore the association between sedative and antiseizure efficacy at a1- . Thus, BZs generally do not increase the amplitude of miniature inhibitory postsynaptic currents (mIPSCs) from individual synapses, but instead prolong the mIPSC decay phase 68 by slowing the dissociation of GABA from the receptor. 69 Prolongation of the mIPSC increases temporal and spatial summation of multiple synaptic inputs, which in turn increases the amplitude of stimulus-evoked polysynaptic IPSCs. The BZs thus increase the inhibitory ''tone'' of GABAergic synapses, which reduces the hypersynchronous firing of neuron populations that underlies seizures. 1 An alternative mechanism for BZ enhancement of GABA A R currents has been proposed based on the controversial finding that BZs progressively increase GABA A R ''single channel'' conductance. 70 Unlike prior reports of a 27 pS main conductance level and a 19 pS subconductance level, 65 Eghbali et al. 70 found conductance levels ranging from 8 to 53 pS in response to GABA alone, and 70-80 pS in the presence of diazepam, with up to 7-fold increase in conductance observed when diazepam was added. The increases in conductance were seen predominantly in cellattached patches onto neurons expressing native receptors, but were also observed in outside-out patches. They found similar increases in channel conductance induced by pentobarbital, 71 neuroactive steroids, 72 propofol, 73 and GABA itself. 74 The same group 75 subsequently found that high conductance (>40 pS)
GABA A R channels were not observed in recombinant a1-b1-g2
GABA A Rs expressed in L929 cells, nor was conductance increased by diazepam unless the GABA A R-associated protein (GABARAP) was also co-expressed, apparently facilitating clustering of GABA A R proteins through its interaction with the cytoplasmic loop of the g2 subunit as occurs at synapses with native receptors. Since peptides mimicking the intracellular g2 loop (g2 381-403)
self-associate, and application of this peptide to the cytoplasmic surface of inside-out patches prevented the diazepam-induced increase in conductance, they hypothesized that the apparent single channel conductance changes induced by BZs are due to synchronized openings of multichannel clustered GABA A Rs via concerted action through the interacting cytoplasmic loops of conjoined receptors. Such interactions might occur through shared transmembrane domains between interacting receptors, as observed in G-protein-coupled receptors. 76 This hypothesis could be addressed using concatenated subunits, chimeras and other strategies. However, synchronization of multiple identical channels by such a mechanism should still require a discrete 9 pS unitary conductance of which the larger conductance states are integer multiples, which has not been reported.
Barbiturates
Phenobarbital was synthesized by Emil Fischer at Bayer in 1911 and introduced as an ASD by Alfred Hauptmann in 1912. Its tendency to produce sedation and cognitive slowing or confusion, as well as paradoxical hyperactivity in children, has curtailed its use in favor of more modern alternatives. 77 In addition to their enhancement of GABA A R currents, barbiturates also inhibit repetitive action potential firing at neuronal sodium channels 78 by reducing fractional open time and shifting the potential of halfmaximal opening towards hyperpolarized potentials. 79 These actions contribute to both their antiseizure action and their adverse effect profile.
When co-applied with low concentrations of GABA, barbiturates increased the mean open time, but had no effect on the lengths of 3 distinct open state durations. 80 The increase in mean open time resulted from fewer openings in the shorter two durations (O1 and O2) and more long duration (O3) openings.
There was also an increase in long burst durations, but no change in the single channel opening frequency or in the closed frequency duration histogram. The increase in channel open time results in greater chloride current flux and increased likelihood that channel openings will summate, producing larger inhibitory currents. In the absence of GABA, high concentrations of pentobarbital (EC 50 0.33 mM) and phenobarbital (EC 50 3 mM) directly activated GABA A R chloride currents with lower efficacy (smaller maximal currents) than GABA 82 . Barbiturate-activated GABA A R currents were blocked by bicuculline and picrotoxin, and at high concentrations both phenobarbital and pentobarbital produced open channel block that rapidly terminated the induced currents. The concentrations involved in both direct activation and open channel block are far higher than usual therapeutic levels, thus the main antiseizure mechanism is likely the GABA A R allosteric effect in concert with synaptic and extrasynaptic GABA. Unlike the BZs, barbiturate sensitivity does not require a specific subunit composition. Homomeric b1 receptors expressed in Xenopus oocytes were directly activated by pentobarbital even though they were not responsive to GABA; these currents were blocked by picrotoxin or penicillin but not bicuculline. 83 Pentobarbital also induced current in both a1-b3 and b3
homomeric GABA A Rs. 84 barbiturate responsiveness by altering the efficacy of GABA for activating the channel. Chimera and mutagenesis studies have identified domains and residues that contribute to barbiturate action, though in less detail than for the BZs. Mutation of the proline (P228A) in the first transmembrane domain of the b1 subunit reduced barbiturate enhancement of GABA-evoked currents in a1-b1-g2L GABA A Rs while increasing apparent GABA affinity, without otherwise altering single channel kinetics. 88 A chimera study using constructs created from the amino terminal end of the b3 subunit and the carboxyl terminal end of the r1 subunit, which forms homomeric GABA C receptors that are insensitive to barbiturates, found that residues of the b3 subunit involved in pentobarbital binding to GABA A Rs are located downstream from the middle of the M2 region. 89 Similarly, mutation of a r1 tryptophan (W328) in the third transmembrane domain to a hydrophobic residue produced both allosteric and direct channel activation by pentobarbital. 90 
Loreclezole
Loreclezole has antiseizure activity in a variety of seizure models, acting more like a barbiturate than a BZ in that the increase in seizure threshold produced by loreclezole was potentiated rather than blocked by the BZ antagonist, flumazenil. 91 In the hippocampal slice, loreclezole, potentiated paired pulse inhibition 92 and inhibited epileptiform discharges induced by low Ca 2+ or low Mg 2+ . Loreclezole strongly potentiated recombinant GABA A Rs containing a b2 or b3 subunit but did not enhance currents from b1-containing receptors. 93 A single asparagine residue (b2(N289) or b3(N290)) at the cytoplasmic end of the 2nd transmembrane domain confers sensitivity to loreclezole; this amino acid is a serine in the b1 subunit. 94 Mutation of b1S290 to N conferred loreclezole sensitivity to b1-containing GABA A Rs, while mutation of b2N289 or b3N290 to S eliminated loreclezole enhancement. When both b1 and b3 were co-expressed in the same receptor, loreclezole sensitivity was abolished, suggesting a dominant effect of the b1 subunit. 95 Coexpression with different alpha subunits altered the degree of loreclezole potentiation (a1 = a2 = a3 > a5 > a4);
96 expression of a5 and b3 with the p subunit reduced loreclezole potentiation, 97 while a1-b3-e receptors showed normal loreclezole enhancement. 87 At higher concentrations (> 6 mM) loreclezole caused concentration-dependent inhibition of GABA A R currents by enhancing the rate of apparent desensitization. 98 The effect
was inconsistent with open channel block as it was voltage independent, non-competitive, and increased with increasing GABA concentration. The BZ site was not involved as the inhibition was not antagonized by flumazenil and did not require a g subunit. This finding has important clinical implications, since inadvertent high levels of drug could inhibit rather than enhance GABA A R function and potentially trigger seizure activity.
Loreclezole inhibited a1-b1-g2L found to inhibit r1 homomeric GABA C receptors with an IC 50 of 0.5 mM, which was proposed as a rapid means of pharmacological identification of these receptors. 99 
Ganaxolone
Ganaxolone (3a-OH-3b-methyl-5a-pregnan-20-one) is the 3b-methylated synthetic analog of the neurosteroid, allopregnanolone, a natural metabolite of progesterone that allosterically enhances GABA A R current. It has a broad range of antiseizure activity in animal epilepsy models 100 including seizures induced by bicuculline, t-butylbicyclophosphorothionate (TBPS, a high affinity ligand for the GABA A R picrotoxin site), aminophylline and corneal kindling, and is well tolerated and effective against seizures in humans. Ganaxolone is currently under evaluation for partial onset seizures. It may have special utility in women with catamenial epilepsy who have increased seizures during periods of low progesterone in the menstrual cycle, as well as in children with infantile spasms. 101 The antiseizure effect of neurosteroids is not due to action at the progesterone receptor (PR), as exogenous allopregnanolone prevented seizures in PR knockout mice. 102 Moreover, progesterone's antiseizure effect requires metabolism to allopregnanolone, as it was blocked by finasteride, a 5a-reductase inhibitor that blocks allopregnanolone synthesis from progesterone. Hence, the antiseizure effect of allopregnanolone (and ganaxolone) is mediated by GABA A Rs. Specific neurosteroids can allosterically modulate GABA A R activity, either positively or negatively, via distinct binding sites on GABA A Rs. 104 Since a variety of GABA A R-interacting steroid hormones are synthesized in the brain, 105 these agents represent endogenous modulators of GABA A R function. Allopregnanolone is synthesized in two steps from progesterone: 5a-reductase converts progesterone to 5a-dihydroprogesterone, then 3-ahydroxysteroid oxidoreductase reversibly converts 5a-dihydroprogesterone to 3a-OH-5a-pregnan-20-one (allopregnanolone). Addition of the 3b-methyl group on ganaxolone does not alter binding to GABA A Rs, but prevents further metabolism of the 3a-OH group and thus prolongs its GABA A R-modulating actions. 100 Ganaxolone enhanced GABA and BZ binding via positive allosteric modulation of GABA A R activity, and at nanomolar concentrations potentiated GABA-evoked currents at a1-b1-g2L, a2-b1-g2L or a3-b1-g2L GABA A Rs expressed in Xenopus oocytes, while direct activation of chloride flux occurred to a limited extent only at micromolar concentrations. 100 The effects of GABA A R-enhancing neurosteroids on single channel GABA A R currents were studied using androsterone (5a-androstan-3a-ol-17-one) and pregnanolone (5b-pregnan3a-ol-20-one) but likely apply to other positive steroid GABA A R modulators including ganaxolone. Like the barbiturates and loreclezole, these agents increased the proportion of openings to the two longer open states (O2 and O3) without altering the intrinsic durations of those states, and produced longer burst durations. 106 There was no change in single channel conductance. Unlike the barbiturates, however, the neurosteroids also increased single channel opening frequency and reduced closed time durations in all but the shortest closed time distributions (thought to represent intraburst closures).
At high concentrations (10 109 At high concentrations (1 mM), THDOC inhibited this isoform. There is currently consensus that d subunit-containing receptors are more sensitive to neurosteroid enhancement, though other subunits are also involved in mediating neurosteroid actions.
Presence of the a6 subunit reduced neurosteroid sensitivity. 110 THDOC (1 mM) enhanced a1-b3-d more than a6-b3-d currents, but increased the extent of desensitization and prolonged deactivation for both receptor isoforms; a1-a6 and a6-a1 chimeras (spliced in transmembrane domain M1) suggested that differences in deactivation rate and its voltage-dependence correlated with N-terminal domains, while the extent of desensitization and its voltage-dependence correlated with C-terminal domains. 111 In dentate granule cells from epileptic animals, an increase in a4 subunit expression was associated with decreased neurosteroid enhancement. 112 In receptors composed of one a subunit (from a2 through a5), b2 and g2S, neurosteroid potentiation was dependent on the conserved glutamine residue (a1(Q241)) in the first transmembrane domain of the respective a subunit. 113 The d subunit did not affect neurosteroid binding but likely influenced the efficacy of neurosteroid potentiation. Mutation of a1Q241 to L abolished neurosteroid potentiation, while mutation to W mimicked the effect of steroids and prevented further augmentation; the neighboring S240 residue also participated in steroid binding. 114 A subsequent study using concatenated subunits demonstrated that a single functional binding site (not disrupted by the Q241 mutation) was sufficient for neurosteroid modulation. 115 6. GABA A R effects of other ASDs
Topiramate
Topiramate is a heterotricyclic sulfamate with several mechanisms of action including inhibition of sodium and calcium channels, inhibition of carbonic anhydrase, and augmentation of GABA-evoked currents. Topiramate's effects on GABA A Rs may contribute both to its antiseizure efficacy and its side effect profile including memory problems, fatigue and psychomotor slowing. It is approved for partial and generalized seizures, the Lennox Gastaut syndrome, and migraine.
Topiramate inhibited voltage-gated sodium channels, with a left shift of the steady state inactivation curve 116 resulting in intermittent blockade of sustained repetitive action potential firing during prolonged depolarization. 117 It also blocked repetitive firing in hippocampal CA3 neurons from spontaneously epileptic rats, and reduced excitatory post-synaptic potentials and responses to bath-applied glutamate, suggesting blockade of post-synaptic glutamate receptors, 118 affecting kainate-evoked but not NMDA-evoked currents. 119 Topiramate also inhibited both L-type and non L-type high voltage activated calcium currents 120 and reduced bicarbonate production via inhibition of carbonic anhydrase, 121 which may contribute to its antiseizure effect.
Topiramate (10 mM) enhanced chloride flux into cerebellar granule neurons stimulated by 10 mM GABA, but did not significantly increase chloride influx alone. 122 It also enhanced GABA-evoked currents in cultured cortical neurons that were insensitive to the BZ, clonazepam, and clonazepam-potentiated GABA currents in topiramate-insensitive neurons, confirming that topiramate's site of action on GABA A Rs is independent of the BZ site. 123 Subunit selectivity studies have been inconsistent.
Topiramate (1-100 mM) reversibly inhibited Cl À currents evoked by 1-10 mM GABA in Xenopus oocytes expressing a1-b2-g2S and a2-b2-g2S GABA A Rs, and reduced the apparent desensitization (''current-fading rate'') in a1-b2-g2S-expressing oocytes, but potentiated GABA-evoked Cl À currents and increased the desensitization rate in a6-b2-g2S GABA A Rs, with no effect on a4-b2-g2S
receptors or mixed population GABA A Rs expressed from rat brain mRNA. 124 In contrast, another study found that topiramate could both potentiate and directly activate b2 or b3-containing heteromeric GABA A Rs, with greatest effect on a4-b3-g2S; 125 positive or negative effects on b1-containing GABA A Rs depended on the co-expressed alpha subunit. Additional studies are needed to clarify the site and mechanism of action.
Felbamate
Felbamate was launched as a promising novel ASD in 1993 with an uncertain mechanism of action, but its use was curtailed after early reports of aplastic anemia 126 and hepatic failure. 127 Felbamate inhibited binding of the GABA antagonist [ 3 H]T-BOB with a regional pattern different from that produced by GABA agonists, bicuculline, zinc or neurosteroids, 128 and enhanced GABA-elicited Cl À currents in cultured cortical neurons. Felbamate enhancement was not blocked by flumazenil, and felbamate did not affect pentobarbital potentiation or PTX inhibition of GABAevoked currents, suggesting an independent site of action. It prolonged the mean burst duration of GABA-activated single channel currents, suggesting a barbiturate-like effect. 129 Felbamate also blocked N-methyl-D-aspartate (NMDA) receptor currents, an alternative possible antiseizure mechanism. 130 Derivative compounds including fluorofelbamate and carisbamate that are not associated with hematopoietic or hepatic toxicity may revive interest in felbamate-like agents. 131 
Ezogabine
Ezogabine (also known as retigabine) is a novel ASD effective in a variety of animal models. Its primary effect is enhanced activation of heteromeric potassium channels composed of the KCNQ2 and KCNQ3 subunits 132 which underlie the ''M current'' that is a major determinant of resting membrane potential and neuronal excitability. However, ezogabine also dose-dependently and reversibly potentiated GABA A R-dependent IPSC peak amplitude, decay times and total charge transfer. 133 EPSCs were unaffected, and paired pulse depression was unchanged, suggesting a post-synaptic effect at GABA A Rs. Ezogabine potentiated GABA-induced currents in rat cortical neurons in a concentrationdependent fashion at 10 mM and above. 132 This action was not antagonized by flumazenil, indicating a non-BZ site of action. Subunit dependence and binding site are not known.
Losigamone
Losigamone is a novel ASD which inhibited the persistent component of sodium currents in hippocampal neurons at depolarized potentials, suppressed sustained repetitive firing 134 and decreased the frequency of spontaneous action potentials without affecting miniature post-synaptic current amplitudes. 135 Losigamone stimulated 36 Cl À influx into spinal cord neurons in the absence of GABA, and potentiated 36 Cl À influx stimulated by submaximal GABA concentrations; both effects were blocked by bicuculline or picrotoxin. 136 no difference in the effect of the + or -stereoisomers or the racemic mixture. The site of action at GABA A Rs is unknown.
Stiripentol
Stiripentol is as an adjunct ASD which was thought to act by inhibiting cytochrome P450 enzymes involved in metabolism of conventional ASDs. Recently, stiripentol was found to enhance recombinant GABA A R currents, with greater potentiation of a3-containing receptors and reduced potentiation with the b1 or e subunits. 137 It caused a leftward shift in the GABA concentrationresponse relationship without increasing maximal GABA-evoked currents, and did not involve sites associated with neurosteroid or loreclezole potentiation. 137 Saturating barbiturate sites with pentobarbital occluded stiripentol enhancement, and stiripentol increased the duration but not the frequency of opening of GABA A R channels, suggesting a barbiturate-like mechanism. 138 
GABA-enhancing agents
An additional mechanism for enhancing GABA A R-mediated inhibition involves increasing the concentration or duration of GABA in the synaptic cleft and perisynaptic/extrasynaptic sites. Enhancing GABA synthesis or blocking its reuptake or catabolism could prolong GABA IPSPs and increase perisynaptic spill-over, increasing tonic/extrasynaptic GABA currents which likely play a major role in seizure prevention.
Gabapentin and pregabalin
Gabapentin was designed as a GABA analog, and some studies have suggested that it modulates the action of the GABA synthetic enzyme, glutamic acid decarboxylase (GAD) and the glutamate synthesizing enzyme, branched-chain amino acid transaminase, resulting in increased GABA synthesis. 139 Gabapentin increases non-synaptic GABA responses from neuronal tissues in vitro and increases GABA levels in brain. 140 Its other (likely primary) mode of action involves binding to the a2-d binding site on L-or P/Q-type presynaptic voltage-gated calcium channels, presumably inhibiting excessive neurotransmitter release 141 by interfering with calcium channel functional expression or trafficking 142 . Pregabalin, which binds to the a2-d calcium channel subunit with higher potency, may have similar mechanisms of action. Most studies emphasize the calcium channel as the primary site, 143 though a contributory effect on GABA metabolism is possible. 144 
Valproic acid
Valproic acid may affect GABA production, among other ASD mechanisms. Valproate caused non-significant increases in cerebral GABA levels but elevated brain GAD activity significantly. 145 Valproic acid increased GABA synthesis and release in brain regions including substantia nigra, 146 which is thought to be involved in the control of seizure generation and propagation. 147 It also reduced the release of gamma-hydroxybutyric acid and attenuated neuronal excitation induced by NMDA-type glutamate receptors. 147 Additional ASD mechanisms include enhancing sodium channel inactivation (like phenytoin) and reducing T-type Ca 2+ channel currents (like ethosuximide), 148 perhaps explaining its utility against both partial onset and absence seizures.
Tiagabine
Tiagabine is a derivative of nipecotic acid that binds to the presynaptic GAT-1 GABA transporter and blocks GABA reuptake, without acting as a ''false neurotransmitter.'' In control hippocampal slices, tiagabine alone induced a significant chloride conductance, suggesting that GAT-1 activity controls the basal level of extracellular GABA. 149 Tiagabine prolonged hippocampal IPSC duration in a lamina-specific fashion, with greater effect in stratum radiatum (167%) than stratum oriens (115%). 150 Tiagabine reduced the frequency of epileptiform discharges in hippocampal slices exposed to low Mg 2+ or 4-aminopyridine. 151 The ability of tiagabine to prolong GABA currents was preserved in hippocampal slices from pilocarpinetreated epileptic rats, hence the GAT-1 transporter remains a functional target for regulating GABA levels in this model of temporal lobe epilepsy. 152 Tiagabine was effective as an adjunct agent against partial onset seizures, though its prolonged titration period, requirement for multiple daily doses and CNS side effect profile (dizziness, tremor, somnolence, mood disturbances and rare psychotic symptoms) have limited its use. 153 
Vigabatrin
Vigabatrin (g-vinyl-GABA) has a unique mechanism of action, functioning as a ''suicide inhibitor'' of GABA transaminase, the primary enzyme for GABA catalysis. This leads to permanent inhibition of the affected enzyme, requiring synthesis of new GABA transaminase and hence prolonging the biological half-life beyond its pharmacokinetic half-life of 8 hours. 154 It is effective against complex partial seizures, 155 Lennox-Gastaut syndrome and West Syndrome, for which it has become an alternative to ACTH 156 particularly in children with tuberous sclerosis. 157 Vigabatrin increases the extracellular concentrations of GABA both in vitro 158 and in vivo. 159 The anti-seizure effects of increasing GABA concentration may be complex. Biphasic responses to vigabatrin administration have been observed, with an early proconvulsant effect. 160 A biphasic effect was also seen on after-discharge duration with an early facilitation of the limbic pattern of epileptiform discharge and later suppression at higher doses. 161 Elevated GABA concentrations may increase neuronal synchronization, particularly of thalamic neurons in absence epilepsy, and there have been several reports of vigabatrin worsening absence seizures or precipitating absence status epilepticus. 162 A major limitation to the use of vigabatrin is the relatively high incidence of vision disturbance associated with chronic use. In 21 of 30 children treated with vigabatrin who were screened for vision disturbances despite no report of visual symptoms, 4 had visual field constrictions, which did not improve after discontinuation of the drug. 163 One study associated visual disturbances with infantile spasms rather than the drug. 164 The prevalence of vision problems ranged from 10 to 40% of pediatric and adult patients exposed to vigabatrin. 165 This adverse effect may be directly related to elevated GABA concentrations, as hippocampal neurons grown in depolarizing conditions (25 mM KCl) showed 20% loss of MAP-2-positive neurons in the presence of vigabatrin, which was mimicked by GABA (100 mM) and blocked by bicuculline or picrotoxin. 166 The cellular mechanism of this toxicity is not entirely clear, but in situations in which GABA is depolarizing, excessive GABA could promote calcium entry through L-type (slowly desensitizing) voltage-gated calcium channels, 167 However, BZ and barbiturate antiseizure efficacy appear to be intact, likely because persistent opening of GABA A R channels (in the presence of allosteric agents) may reduce the depolarizing chloride reversal potential, resulting in ''shunt'' inhibition. Alternatively, subthreshhold GABA-evoked depolarization may inactivate sodium channels and prevent action potential firing. 174 The current through GABA A R channels can also be altered by changes in intracellular bicarbonate, [HCO 3 À ], 169 which can flow through the channel. 175 Changes in [HCO 3 À ] may underlie reduced synaptic GABA currents during development of BZ tolerance. 176 Depolarizing GABA A R currents may also be a source of interictal spike activity, as observed in epileptic subiculum neurons in hippocampal brain slices from patients with temporal lobe epilepsy. 177 Changes in the GABA current reversal potential might also explain why diazepam can be less effective in children with epileptic encephalopathies, 178 and rarely can cause status epilepticus in patients with the Lennox Gastaut syndrome. 179 Bumetanide, an inhibitor of NKCC-1 used clinically as a potent loop diuretic, has been proposed as an adjunctive agent to reduce intraneuronal chloride accumulation and reverse the depolarizing chloride gradient that makes GABA A Rs excitatory, particularly in the neonatal setting. 170 Bumetanide improved the responsiveness of hippocampal slices to phenobarbital in reducing epileptiform discharges induced by low Mg 2+ , 180 and also suppressed electrographic seizures in neonatal rats. 172 Depolarizing GABA currents may occur in cortical more than subcortical brain regions, possibly explaining the electroclinical uncoupling that occurs with phenobarbital in neonatal seizures. 181 Bumetanide has been used successfully in a single reported human neonate with seizures, 182 and a clinical trial (NCT00830531) is in progress. However, elimination of the depolarizing Cl À gradient during development may have adverse consequences; a permanent reduction in AMPAR-mediated excitatory neurotransmission and sensorimotor gating deficits were observed after bumetanide exposure in neonatal rats. 183 Such potential adverse effects will have to be weighed against the benefits associated with seizure termination or prevention.
GABA A R subunit changes and ASD efficacy in epilepsy and status epilepticus
There is considerable evidence that GABA A R composition and function change with epilepsy, both acutely in the setting of status epilepticus and in chronic epilepsy. During status epilepticus, there is a rapid change in GABA A R function that reduces BZ sensitivity, 184 apparently due to activity-dependent internalization of GABA A Rs and replacement with BZ-insensitive receptors. 185 Kainic acidinduced status epilepticus in young (postnatal day 9) rats altered the normal developmental pattern of GABA A R subunit maturation, 186 preventing the normal switch from a2 to a1-containing GABA A Rs. These changes correlate with the finding in animal models 15, 184, 187 and humans 188, 189 that BZs are effective early in the course of status epilepticus but lose their potency and efficacy for termination of status with longer seizure duration. These findings increase the urgency for treatment of status epilepticus early in its course, and also suggest the need to find alternative treatments that retain efficacy in refractory status epilepticus, or methods to prevent or reverse the GABA A R changes that occur with prolonged seizures.
In the pilocarpine model of temporal lobe epilepsy, the a1 subunit in dentate granule neurons was downregulated and a4 subunit was upregulated, 190 while in younger (postnatal day 20) animals, the a1 subunit was increased after status epilepticus. 191 GABA A R subunit changes after pilocarpine-induced status are associated with altered physiological properties including reduced neurosteroid sensitivity and an increase in a4-containing receptors colocalized with synapses rather than extracellular sites. 112 Such changes might contribute to the propensity for spontaneous seizures or alternatively represent a functional adaptation to reduce seizure expression. Substitution of a1 with a4 might reduce synaptic (phasic) but increase extrasynaptic (tonic) inhibition, and BZ sensitivity would be lost in a4-containing receptors. Using an adenovirus vector to insert the a1 subunit gene driven by the a4 promoter resulted in a decrease in seizure frequency, suggesting that the GABA A R subunit changes were contributory toward epileptogenesis. 192 Hence, altering GABA A R subunit expression in brain regions critical to seizure development may provide a new therapeutic strategy for seizure prevention. Alternatively, novel ASDs targeting the specific epilepsy-associated subunit composition might provide a less invasive approach toward seizure control. Long term exposure to the GABA A R allosteric agents themselves can alter GABA A R composition and function. In rat pups exposed to therapeutic concentrations of diazepam or phenobarbital from postnatal day 10 through 40, then tapered for 2 weeks and euthanized on postnatal day 90 showed increased mRNA expression in dentate granule neurons for GAT-1, 3 and 4, GABA A R subunits a4, a6, b3, d and u and GABA B receptor subunit R1, and decreased mRNA expression for GAD65, GAD67 and GABA A R subunits a1 and a3. 193 Tolerance-and dependence-associated changes in GABA A R subunit composition with chronic use of BZs 194, 195 and barbiturates 196, 197 have been reported, and may reflect tolerance to either the antiseizure or adverse CNS effects. However, these findings suggest that not only seizures, but their prolonged treatment with GABAergic agents, can alter inhibitory neuronal function for extended periods or even permanently, with possible cognitive and behavioral consequences that must be considered when contemplating chronic GABAergic ASD use.
